⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 27, 2022Clinical Infectious DiseasesOpen Access

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial

Ahmed Musa Jane Mbui Rezika Mohammed Joseph Olobo Koert Ritmeijer Gabriel Alcoba Gina Muthoni Ouattara Thaddaeus Egondi P Nakanwagi Truphosa Omollo Monique Wasunna Luka Verrest Thomas P. C. Dorlo Brima M. Younis A. R. O. Abdel Nour Elmukashfi Taha Ahmed Elmukashfi Ahmed Ismail Omer Haroun Eltahir Awad Gasim Khalil Simon Njenga Helina Fikre Tigist Mekonnen Dagnew Mersha Kasaye Sisay Patrick Sagaki Jorge Alvar Alexandra Solomos Fabiana Alves

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct03129646.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Musa et al. (2022) studied this question.

synapsesocial.com/papers/69d9a0e89a6164e50fa3d20e https://doi.org/10.1093/cid/ciac643

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South AsiaClinical Trial · 2011 · 73 citations
2Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trialRCT · 2011 · 71 citations
3Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized TrialRCT · 2016 · 106 citations
4Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic studyOriginal Research · 2017 · 35 citations
5Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern AfricaOriginal Research · 2020 · 18 citations

More related papers

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial2010
Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial2012
Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis2012

More from Clinical Infectious Diseases

Not All Extrapulmonary Tuberculosis Is Equal: Site-Specific Mortality in a National Indian CohortMon,
Association Between Neighbourhood-level Antibiotic Utilization and the Rate of Community-Associated C. difficile (CA-CDI) Infection: An Ecological StudyMon,